Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy?

Mohsen, Waled; Williams, Astrid-Jane; Wark, Gabrielle; Sechi, Alexandra; Koo, Jenn-Hian; Xuan, Wei; Bassan, Milan S.; Connor, Susan J.

doi:10.3748/wjg.v27.i11.1090

Cited by 6 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mohsen et al [ 17 ] also later weighed the efficacy and safety of an osmotically active solution of sodium picosulphate and magnesium citrate (with PEG added) in 56 patients with IBD. These determined less abdominal pain than the PEG-ascorbate comparison, albeit with a greater serum increase in magnesium and no significant differences in efficacy and safety between the groups.…”

Section: What Profile Do Non-peg Solutions Have In Ibd?mentioning

confidence: 99%

Emerging space for non-polyethene-glycol bowel preparations in inflammatory bowel disease-related colonoscopy: Veering toward better adherence and palatability

Pellegrino,

Gravina

2023

World J Gastroenterol

View full text Add to dashboard Cite

Patients with inflammatory bowel diseases (IBDs) require repeated endoscopic evaluations over time by colonoscopy to weigh disease activity but also for different and additional indications (e.g. , evaluation of postoperative recurrence, colorectal cancer surveillance). Colonoscopy, however, requires adequate bowel preparation to be of quality. The latter is achieved as long as the patient takes a certain amount of product to have a number of bowel movements suitable to clean the colon and allow optimal visualization of the mucosa during endoscopy. However, significant guidelines recommend preparations for patients with IBD not excelling in palatability. This recommendation originates from the fact that most of the studies conducted on bowel preparations in patients with IBD have been done with isosmolar preparations based on polyethylene glycol (PEG), for which, therefore, more safety data exist. As a result, the low-volume non-PEG preparations (e.g. , magnesium citrate plus picosulphate, oral sulphate solutions) have been set aside for the whole range of warnings to be heeded because of their hyperosmolarity. New studies, however, are emerging, leaning in overall for a paradigm shift in this matter. Indeed, such non-PEG preparations seem to show a particularly encouraging and engaging safety profile when considering their broad potential for tolerability and patient preference. Indeed, such evidence is insufficient to indicate such preparations in all patients with IBD but may pave the way for those with remission or well-controlled disease. This article summarizes the central studies conducted in IBD settings using non-PEG preparations by discussing their results.

show abstract

Section: What Profile Do Non-peg Solutions Have In Ibd?mentioning

confidence: 99%

Emerging space for non-polyethene-glycol bowel preparations in inflammatory bowel disease-related colonoscopy: Veering toward better adherence and palatability

Pellegrino,

Gravina

2023

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Colonoscopies are an important diagnostic method in the detection of colorectal cancer (CRC) and colonic disease 1 . In 2016, CRC was the third most common diagnosed cancer in Australia, with a 70% 5‐year survival rate 2 .…”

Section: Introductionmentioning

confidence: 99%

“…Colonoscopies are an important diagnostic method in the detection of colorectal cancer (CRC) and colonic disease. 1 In 2016, CRC was the third most common diagnosed cancer in Australia, with a 70% 5‐year survival rate. 2 The high mortality rate associated with this type of cancer reinforces the importance of diagnostic accuracy in the early detection of neoplasms, which can be compromised when colonic preparation quality is inadequate.…”

Section: Introductionmentioning

confidence: 99%

Bowel cleansing efficacy of 1 L NER1006versus macrogol and 3 L polyethylene glycol using split‐dose administration

2022

View full text Add to dashboard Cite

Background and Aim Colonoscopies are an important diagnostic technique in the detection of colorectal cancer and colonic disease. Adequate examination is dependent on the degree of mucosal visibility, with poor cleansing impeding the detection of neoplasms. These patients require shorter colonoscopy surveillance intervals, longer hospital stays, and increased healthcare costs—rendering a screening colonoscopy cost‐ineffective. In Australia and the Gold Coast Hospital and Health Service (GCHHS), macrogol and 3 L of polyethylene glycol are the preferred regimen given its safety profile and efficacy. Yet, little is known locally about the use of the new low‐volume bowel preparation NER1006 (Plenvu) given its recent registration with the Therapeutic Goods of Australia (TGA). The primary outcome assessed the bowel cleansing efficacy of NER1006 compared with 7 days of macrogol and 3 L of polyethylene glycol using the Boston Bowel Preparation Scale (BBPS), while also assessing the influence of notable patient characteristics such as age, gender, body mass index (BMI), and the patients Charlson comorbidity index (CCI). Secondary outcomes assessed the polyp detection rate and procedural factors including cecal intubation, scope withdrawal time, and rebooking rates. Methods Data from all patients who underwent an outpatient colonoscopy procedure at GCHHS between 1 July 2020 and 30 September 2020 were analyzed. Patients were aged 50–74 years of age and were referred for a screening colonoscopy due to a positive fecal occult blood test (FOBT) result from the National Bowel Cancer Screening Program. Results Of the 238 patients who met the inclusion criteria, 108 patients received NER1006 and 130 patients received macrogol and 3 L polyethylene glycol. NER1006 achieved superior overall (P < 0.001) and right‐sided colon cleansing (P = 0.016). There was an even distribution of males and females (P = 0.118), the mean age of both cohorts was <65 years of age. The macrogol and 3 L polyethylene glycol group had a statistically higher BMI (P < 0.001) and CCI (P < 0.001). Cecal intubation success was achieved in both cohorts (≥95%) and scope withdrawal time was ≥6 min, polyp detection was non‐superior (P = 0.824), but superior in NER1006 when BBPS ≥6 (P = 0.002). Rebooking rates were significantly lower in the NER1006 group (P = 0.013). Conclusion This study demonstrated that NER1006 was superior in terms of overall and right‐sided bowel cleansing as a primary endpoint. Patient factors demonstrated to be independent predictors of inadequate bowel preparation. Future studies should aim to explore the safety and tolerability of NER1006 while also assessing the bowel cleansing effectiveness in patients with a high BMI and comorbidity index.

show abstract

Endoscopic Disease Activity and Biologic Therapy Are Independent Predictors of Suboptimal Bowel Preparation in Patients with Inflammatory Bowel Disease Undergoing Colonoscopy

et al. 2022

View full text Add to dashboard Cite

Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy?

Cited by 6 publications

References 25 publications

Emerging space for non-polyethene-glycol bowel preparations in inflammatory bowel disease-related colonoscopy: Veering toward better adherence and palatability

Emerging space for non-polyethene-glycol bowel preparations in inflammatory bowel disease-related colonoscopy: Veering toward better adherence and palatability

Bowel cleansing efficacy of 1 L NER1006versus macrogol and 3 L polyethylene glycol using split‐dose administration

Endoscopic Disease Activity and Biologic Therapy Are Independent Predictors of Suboptimal Bowel Preparation in Patients with Inflammatory Bowel Disease Undergoing Colonoscopy

Contact Info

Product

Resources

About